A higher tumor response rate for PD-(L)1 inhibitor combination therapy than monotherapy in NSCLC with PD-L1 expression ≥50% has been suggested [16] essentially based on comparisons of KEYNOTE-024 and 042 with KEYNOTE-189 and 407 [6–8, 10]. This evidence concerns the gene CD274 and neoplasm.